Dry Needling and Manual Therapy for the Management o Cervicogenic Headache.
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Ramesh Chandra Patra
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Â Pain (Numerical Pain Rating scale).
Study Overview
Brief Summary
The cause of CGH isthought to lie in any of the structures that are innervated by the first three cervicalnerves. This study examines about the dry needling and manual therapy for themanagement of patient with Cervicogenic Headache. As previous studies fails toinvestigate about the dry needling and manual therapy for the management ofpatient with Cervicogenic Headache, this study intends to discuss in detail aboutthe proposed topic and also proposes the model. This study will help the futureresearchers to know about how dry needling and manual therapy helps in themanagement of patient with Cervicogenic Headache as combined modality.Analyzing the existing researches, this research aims to provide a clear overview easymanagementofcervicogenicheadache.
Effects of dryneedling andmanual therapyImprovement in headachedisability index ,Improved range of motion ,Improved quality of life, reduce pain and tenderness for the management of patient withCervicogenic Headache.
Study Design
- Study Type
- Interventional
- Allocation
- Coin toss, Lottery, toss of dice, shuffling cards etc
- Masking
- Investigator Blinded
Eligibility Criteria
- Ages
- 20.00 Year(s) to 50.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Based on the following conditions the individuals are included in the study:
- •Both male and female with the age group of 20-50 years.
- •Persons fulfilling the diagnostic criteria given by IHS (international headache society.
- •Positive FRT (flexion-rotation test) and restricted ROM.
Exclusion Criteria
- •Following participants were excluded from the study:
- •Cervical spine injury, fracture or surgery.
- •Congenital spinal deformity.
- •The participants not meeting age criteria for inclusion.
- •Cervical radiculopathy or presenting neurological deficit.
- •Participants with history of recent trauma.
- •Participants suffering from dizzy spells.
- •Vertebral malignancy.
- •Vertebral-basilar insufficiency.
- •Bone infections.
- •10 Any participants who were taking anti-inflammatory or muscle relaxant medication were excluded.
- •Any participants who failed to comply with the consent form were excluded.
Outcomes
Primary Outcomes
 Pain (Numerical Pain Rating scale).
Time Frame: Before and After the treatment( duration is 4 weeks)
Subjective outcome measures:
Time Frame: Before and After the treatment( duration is 4 weeks)
Quality of life (QOL Questionnaire)
Time Frame: Before and After the treatment( duration is 4 weeks)
Headache disability index (HDI questionnaire)
Time Frame: Before and After the treatment( duration is 4 weeks)
Objective outcome measures:
Time Frame: Before and After the treatment( duration is 4 weeks)
Tenderness (PPT Algometer)
Time Frame: Before and After the treatment( duration is 4 weeks)
Cervical range of motion
Time Frame: Before and After the treatment( duration is 4 weeks)
Secondary Outcomes
- Not Applicable(NA)